Erratum: SMAD4 and its role in pancreatic cancer (Tumour Biol. (2015) 36:1 (111-119) DOI: 10.1007/s13277-014-2883-z);SMAD4 and its role in pancreatic cancer

Tumor Biology

Volumn 36, Issue 1, 2015, Pages 111-119

  Xia, Xiang ^a   Wu, Weidong ^a   Huang, Chen ^a   Cen, Gang ^a   Jiang, Tao ^a   Cao, Jun ^a   Huang, Kejian ^a   Qiu, Zhengjun ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Loss of SMAD4; Pancreatic cancer; Prognosis; TGF signaling pathway

Indexed keywords

SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; SMAD4 PROTEIN, HUMAN;

BINDING SITE; CANCER PROGNOSIS; CARCINOGENESIS; CELL FUNCTION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; PANCREAS CANCER; PANCREAS CELL; PHENOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; PROGNOSIS;

ANIMALS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84925500887     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.3233/TUB-229004     Document Type: Erratum

References (94)

1. Singh P, Srinivasan R, Wig JD. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Pancreas. 2011;40:644–52.
2. Hilbig A, Oettle H. Transforming growth factor beta in pancreatic cancer. Curr Pharm Biotechnol. 2011;12:2158–64.
3. Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, et al. Validation of the 6th edition AJCC pancreatic cancer staging system: report from the National Cancer Database. Cancer. 2007;110:738–44.
4. Goggins M, Kern SE, Offerhaus JA, Hruban RH. Progress in cancer genetics: lessons from pancreatic cancer. Ann Oncol. 1999;10 Suppl 4:4–8.
5. Iacobuzio-Donahue CA, Song J, Parmiagiani G, Yeo CJ, Hruban RH, et al. Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res. 2004;10:1597–604.
6. Kang Y, Ling J, Suzuki R, Roife D, Chopin-Laly X, et al. SMAD4 regulates cell motility through transcription of N-cadherin in human pancreatic ductal epithelium. PLoS One. 2014;9:e107948.
7. Saiki Y, Horii A. Molecular pathology of pancreatic cancer. Pathol Int. 2014;64:10–9.
8. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001;29:117–29.
9. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577–84.
10. Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, et al. (2014) TGF-beta: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst 106: djt369.
11. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350–3.
12. Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM. Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics. 1995;139:1347–58.
13. Derynck R, Gelbart WM, Harland RM, Heldin CH, Kern SE, et al. Nomenclature: vertebrate mediators of TGFbeta family signals. Cell. 1996;87:173.
14. Singh P, Wig JD, Srinivasan R. The Smad family and its role in pancreatic cancer. Indian J Cancer. 2011;48:351–60.
15. Wu G, Chen YG, Ozdamar B, Gyuricza CA, Chong PA, et al. Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science. 2000;287:92–7.
16. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 2000;19:1745–54.
17. Shi Y, Hata A, Lo RS, Massague J, Pavletich NP. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature. 1997;388:87–93.
18. Watanabe M, Masuyama N, Fukuda M, Nishida E. Regulation of intracellular dynamics of Smad4 by its leucine-rich nuclear export signal. EMBO Rep. 2000;1:176–82.
19. Kurisaki A, Kose S, Yoneda Y, Heldin CH, Moustakas A. Transforming growth factor-beta induces nuclear import of Smad3 in an importin-beta1 and Ran-dependent manner. Mol Biol Cell. 2001;12:1079–91.
20. Pierreux CE, Nicolas FJ, Hill CS. Transforming growth factor beta-independent shuttling of Smad4 between the cytoplasm and nucleus. Mol Cell Biol. 2000;20:9041–54.
21. Inman GJ, Nicolas FJ, Hill CS. Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. Mol Cell. 2002;10:283–94.
22. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685–700.
23. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–8.
24. Lecanda J, Ganapathy V, D′Aquino-Ardalan C, Evans B, Cadacio C, et al. TGFbeta prevents proteasomal degradation of the cyclin-dependent kinase inhibitor p27kip1 for cell cycle arrest. Cell Cycle. 2009;8:742–56.
25. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 2000;103:295–309.
26. Bauer J, Sporn JC, Cabral J, Gomez J, Jung B. Effects of activin and TGFbeta on p21 in colon cancer. PLoS One. 2012;7:e39381.
27. Alvarez C, Bass BL. Role of transforming growth factor-beta in growth and injury response of the pancreatic duct epithelium in vitro. J Gastrointest Surg. 1999;3:178–84.
28. Tachibana I, Imoto M, Adjei PN, Gores GJ, Subramaniam M, et al. Overexpression of the TGFbeta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells. J Clin Invest. 1997;99:2365–74.
29. Biswas S, Criswell TL, Wang SE, Arteaga CL. Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin Cancer Res. 2006;12:4142–6.
30. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006;25:435–57.
31. Wagner M, Kleeff J, Lopez ME, Bockman I, Massaque J, et al. Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer. Int J Cancer. 1998;78:255–60.
32. Furukawa T, Sunamura M, Horii A. Molecular mechanisms of pancreatic carcinogenesis. Cancer Sci. 2006;97:1–7.
33. Xu J, Attisano L. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 2000;97:4820–5.
34. Duda DG, Sunamura M, Lefter LP, Furukawa T, Yokoyama T, et al. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene. 2003;22:6857–64.
35. Yasutome M, Gunn J, Korc M. Restoration of Smad4 in BxPC3 pancreatic cancer cells attenuates proliferation without altering angiogenesis. Clin Exp Metastasis. 2005;22:461–73.
36. Shen W, Tao GQ, Li DC, Zhu XG, Bai X, et al. Inhibition of pancreatic carcinoma cell growth in vitro by DPC4 gene transfection. World J Gastroenterol. 2008;14:6254–60.
37. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, et al. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature. 1985;316:701–5.
38. Levy L, Hill CS. Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol. 2005;25:8108–25.
39. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J Cell Sci. 2005;118:3573–84.
40. Chow JY, Quach KT, Cabrera BL, Cabral JA, Beck SE, et al. RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. Carcinogenesis. 2007;28:2321–7.
41. Chow JY, Ban M, Wu HL, Nguyen F, Huang M, et al. TGF-beta downregulates PTEN via activation of NF-kappaB in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol. 2010;298:G275–82.
42. Li H, Huang C, Huang K, Wu W, Jiang T, et al. STAT3 knockdown reduces pancreatic cancer cell invasiveness and matrix metalloproteinase-7 expression in nude mice. PLoS One. 2011;6:e25941.
43. Yang G, Huang C, Cao J, Huang KJ, Jiang T, et al. Lentivirus-mediated shRNA interference targeting STAT3 inhibits human pancreatic cancer cell invasion. World J Gastroenterol. 2009;15:3757–66.
44. Huang C, Jiang T, Zhu L, Liu J, Cao J, et al. STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo. Int J Oncol. 2011;38:1637–44.
45. Zhao S, Venkatasubbarao K, Lazor JW, Sperry J, Jin C, et al. Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res. 2008;68:4221–8.
46. Zhao S, Ammanamanchi S, Brattain M, Cao L, Thangasamy A, et al. Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells. J Biol Chem. 2008;283:11293–301.
47. Vincent DF, Yan KP, Treilleux I, Gay F, Arfi V, et al. Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet. 2009;5:e1000575.
48. Ligr M, Wu X, Daniels G, Zhang D, Wang H, et al. Imbalanced expression of Tif1gamma inhibits pancreatic ductal epithelial cell growth. Am J Cancer Res. 2014;4:196–210.
49. Vincent DF, Gout J, Chuvin N, Arfi V, Pommier RM, et al. Tif1gamma suppresses murine pancreatic tumoral transformation by a Smad4-independent pathway. Am J Pathol. 2012;180:2214–21.
50. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.
51. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265–73.
52. Krantz SB, Shields MA, Dangi-Garimella S, Munshi HG, Bentrem DJ. Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res. 2012;173:105–12.
53. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415–24.
54. Lamouille S, Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol. 2007;178:437–51.
55. Lamouille S, Connolly E, Smyth JW, Akhurst RJ, Derynck R. TGF-beta-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci. 2012;125:1259–73.
56. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006;20:3130–46.
57. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, et al. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol. 2009;11:943–50.
58. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008;68:7846–54.
59. Katsuno Y, Lamouille S, Derynck R. TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 2013;25:76–84.
60. Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010;39:425–35.
61. Loukopoulos P, Kanetaka K, Takamura M, Shibata T, Sakamoto M, et al. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas. 2004;29:193–203.
62. Sun C, Yamato T, Furukawa T, Ohnishi Y, Kijima H, et al. Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep. 2001;8:89–92.
63. Aoki Y, Hosaka S, Tachibana N, Karasawa Y, Kawa S, et al. Reassessment of K-ras mutations at codon 12 by direct PCR and sequencing from tissue microdissection in human pancreatic adenocarcinomas. Pancreas. 2000;21:152–7.
64. Chen WB, Lenschow W, Tiede K, Fischer JW, Kalthoff H, et al. Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells. J Biol Chem. 2002;277:36118–28.
65. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, et al. DPC4 gene in various tumor types. Cancer Res. 1996;56:2527–30.
66. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch. 2001;439:798–802.
67. Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol. 2003;16:902–12.
68. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001;25:579–86.
69. Kloppel G, Luttges J. The pathology of ductal-type pancreatic carcinomas and pancreatic intraepithelial neoplasia: insights for clinicians. Curr Gastroenterol Rep. 2004;6:111–8.
70. Longnecker DS, Adsay NV, Fernandez-del Castillo C, Hruban RH, Kasugai T, et al. Histopathological diagnosis of pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms: interobserver agreement. Pancreas. 2005;31:344–9.
71. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000;60:2002–6.
72. Biankin AV, Biankin SA, Kench JG, Morey AL, Lee CS, et al. Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. Gut. 2002;50:861–8.
73. Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, Wilentz RE, Argani P, et al. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol. 2000;157:755–61.
74. Wilentz RE, Su GH, Dai JL, Sparks AB, Argani P, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol. 2000;156:37–43.
75. Yonezawa S, Higashi M, Yamada N, Goto M. Precursor lesions of pancreatic cancer. Gut Live. 2008;2:137–54.
76. Maitra A, Fukushima N, Takaori K, Hruban RH. Precursors to invasive pancreatic cancer. Adv Anat Pathol. 2005;12:81–91.
77. Singh M, Maitra A. Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology. 2007;7:9–19.
78. Perez-Mancera PA, Guerra C, Barbacid M, Tuveson DA. What we have learned about pancreatic cancer from mouse models. Gastroenterology. 2012;142:1079–92.
79. Ijichi H, Chytil A, Gorska AE, Aakre ME, Fujitani Y, et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev. 2006;20:3147–60.
80. Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell. 2007;11:229–43.
81. Leung L, Radulovich N, Zhu CQ, Wang D, To C, et al. Loss of canonical Smad4 signaling promotes KRAS driven malignant transformation of human pancreatic duct epithelial cells and metastasis. PLoS One. 2013;8:e84366.
82. Voorneveld PW, Stache V, Jacobs RJ, Smolders E, Sitters AI, et al. Reduced expression of bone morphogenetic protein receptor IA in pancreatic cancer is associated with a poor prognosis. Br J Cancer. 2013;109:1805–12.
83. Toga T, Nio Y, Hashimoto K, Higami T, Maruyama R. The dissociated expression of protein and messenger RNA of DPC4 in human invasive ductal carcinoma of the pancreas and their implication for patient outcome. Anticancer Res. 2004;24:1173–8.
84. Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2001;7:4115–21.
85. Singh P, Srinivasan R, Wig JD. SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas. 2012;41:541–6.
86. Hua Z, Zhang YC, Hu XM, Jia ZG. Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. World J Gastroenterol. 2003;9:2764–7.
87. Khorana AA, Hu YC, Ryan CK, Komorowski RA, Hostetter G, et al. Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer. J Gastrointest Surg. 2005;9:903–11.
88. Biankin AV, Morey AL, Lee CS, Kench JG, Biankin SA, et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol. 2002;20:4531–42.
89. Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009;15:4674–9.
90. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806–13.
91. Maitra A, Molberg K, Albores-Saavedra J, Lindberg G. Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease. Am J Pathol. 2000;157:1105–11.
92. Sohn TA, Su GH, Ryu B, Yeo CJ, Kern SE. High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells. Ann Surg. 2001;233:696–703.
93. Wang H, Han H, Von Hoff DD. Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Cancer Res. 2006;66:9722–30.
94. Wang H, Stephens B, Von Hoff DD, Han H. Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells. Pancreas. 2009;38:551–7.